Get the Stockscreener App
9.02
0.67%
0.06
After Hours:
9.01
-0.010
-0.11%
Vir Biotechnology Inc stock is traded at $9.02, with a volume of 2.09M.
It is up +0.67% in the last 24 hours and down -0.77% over the past month.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
See More
Previous Close:
$8.96
Open:
$9.1
24h Volume:
2.09M
Relative Volume:
0.65
Market Cap:
$1.44B
Revenue:
$68.56M
Net Income/Loss:
$-437.99M
P/E Ratio:
-2.8509
EPS:
-3.1639
Net Cash Flow:
$-396.61M
1W Performance:
+0.33%
1M Performance:
-0.77%
6M Performance:
+58.25%
1Y Performance:
+45.95%
1-Day Range:
$8.871
$9.24
1-Week Range:
$8.26
$9.24
52-Week Range:
$4.155
$10.94
Vir Biotechnology Inc Stock (VIR) Company Profile
Name
Vir Biotechnology Inc
Sector
Industry
Phone
415-906-4324
Address
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
9.02 | 1.43B | 68.56M | -437.99M | -396.61M | -3.1639 |
VRTX
Vertex Pharmaceuticals Inc
|
447.26 | 113.44B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
777.25 | 81.68B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
743.12 | 45.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.73 | 43.88B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.86 | 35.25B | 606.42M | -1.28B | -997.58M | -6.403 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-03-25 | Initiated | Evercore ISI | Outperform |
| Aug-27-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-29-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-08-23 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-21-23 | Upgrade | Goldman | Neutral → Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-14-22 | Initiated | SVB Leerink | Outperform |
| Sep-09-22 | Initiated | Morgan Stanley | Underweight |
| Mar-03-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Dec-21-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Oct-25-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Jan-27-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Sep-14-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-11-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-20-20 | Initiated | Needham | Buy |
| Mar-19-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-13-20 | Downgrade | Goldman | Buy → Neutral |
| Feb-27-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Feb-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-19 | Initiated | Robert W. Baird | Neutral |
| Nov-05-19 | Initiated | Barclays | Overweight |
| Nov-05-19 | Initiated | Cowen | Outperform |
| Nov-05-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | JP Morgan | Overweight |
View All
Vir Biotechnology Inc Stock (VIR) Latest News
Energy Moves: Is Vir Biotechnology Inc stock a smart retirement pickPortfolio Update Report & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Bull Bear: Is Vir Biotechnology Inc stock heavily shortedNew Guidance & Consistent Growth Stock Picks - baoquankhu1.vn
Investor Mood: How volatile is LGLWS stockWeekly Earnings Recap & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Vir Biotechnology (VIR) price target increased by 26.10% to 20.74 - MSN
Why did Vir Biotechnology stock surge 60% after-hours today? - MSN
Vanguard affiliates disaggregate holdings; VIR shows 0% ownership (VIR) - Stock Titan
These analysts boost their forecasts on Vir Biotechnology - msn.com
VIR SEC FilingsVir Biotechnology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Vir Biotechnology (NASDAQ:VIR) CAO Sells $70,324.32 in Stock - marketbeat.com
Vir Biotechnology prices $150M stock offering - msn.com
Henry Schein, Vir Biotechnology, Ultra Clean Holdings and other big stocks moving higher on Tuesday - MSN
Insider Sell: Brent Sabatini Sells Shares of Vir Biotechnology I - GuruFocus
Vir Biotechnology (VIR) accounting chief sells 7,711 shares under plan - Stock Titan
Vir Biotechnology (VIR) CFO restructures 5,000 shares via family trust transfer - Stock Titan
Insider sales at VIR (NASDAQ: VIR) include multiple February 2026 transactions - Stock Titan
Valuation Update: Is Vir Biotechnology Inc stock influenced by commodity prices2026 Sector Review & Verified Stock Trade Ideas - baoquankhu1.vn
Hudson Bay Capital Management LP Grows Position in Vir Biotechnology, Inc. $VIR - MarketBeat
Guidance Update: What is the Moat Score of Vir Biotechnology IncPortfolio Value Report & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Vir Biotechnology Stock Pre-Market (+0.2%): Ahead of Leerink Conference Presentation - Trefis
Biggest stock movers Tuesday: HIMS, VIR, CLVT, and more - MSN
VIR-5500 Phase 1 trial yields positive data in prostate cancer, Vir Biotechnology asserts - Traders Union
Vanguard Group Inc. Lowers Stock Position in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology Q4 2025 earnings preview - MSN
HC Wainwright Brokers Boost Earnings Estimates for VIR - MarketBeat
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? - Stocktwits
Vir Biotechnology Names CEO Marianne De Backer as President - theglobeandmail.com
According to the latest filing disclosed by the U.S. Securities and Exchange Commission (SEC), biotechnology company Vir Biotechnology, Inc. has announced a significant personnel appointment. - Bitget
Vir Biotechnology Appoints Marianne De Backer As President In Addition To CEO On March 4, 2026SEC Filing - TradingView
Vir Biotechnology appoints Marianne De Backer as president in addition to CEO on March 4, 2026SEC filing - marketscreener.com
Vir Biotechnology, Inc. Appoints Marianne De Backer as President - marketscreener.com
Vir Biotechnology (NASDAQ:VIR) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
VIR: HC Wainwright & Co. Raises Price Target to $20, Maintains B - GuruFocus
Assessing Vir Biotechnology (VIR) Valuation After Astellas Alliance And VIR-5500 Phase 1 Update - simplywall.st
Vir Biotechnology, Inc. (VIR) Presents at 2026 ASCO Genitourinary Cancers SymposiumSlideshow - Seeking Alpha
VIR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ARCH funds detail 8% Vir Biotechnology (NASDAQ: VIR) stake - Stock Titan
Insider Sell: Vicki Sato Sells 22,000 Shares of Vir Biotechnology Inc (VIR) - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares - MarketBeat
22,000 Vir Biotechnology (VIR) shares sold under 10b5-1 plan - Stock Titan
VIR (NASDAQ: VIR) files Form 144 for 88,000 pre-IPO shares - Stock Titan
Vir Biotechnology closes $172.5 million public offering of common stock - Investing.com South Africa
Vir Biotechnology Inc Stock (VIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.52%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):